Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
Conclusion Based on the PK, PD, and biomarker evaluations, the intermittent administration of galunisertib at 300 mg/day is safe for future clinical investigation.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Brain Tumor | Cancer | Cancer & Oncology | Drugs & Pharmacology | Epilepsy | Epithelial Cancer | Glioma | Investigational New Drugs | Study | Toxicology